Belzutifan

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 200 publications

Near-infrared carbon dots enable ultra-sensitive fluorometric detection of belzutifan: a novel approach for real-time therapeutic drug monitoring in cancer treatment.

Near-infrared carbon dots enable ultra-sensitive fluorometric detection of belzutifan: a novel approach for real-time therapeutic drug monitoring in cancer treatment.

Journal: Analytical methods : advancing methods and applications

Published: December 05, 2025

Role of Targeted Therapy in the Management of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: A Single-Proportion Meta-Analysis.

Role of Targeted Therapy in the Management of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: A Single-Proportion Meta-Analysis.

Journal: Cureus

Published: November 23, 2025

Metabolic reprogramming in clear cell renal cell carcinoma: core pathways and targeted therapeutic strategies.

Metabolic reprogramming in clear cell renal cell carcinoma: core pathways and targeted therapeutic strategies.

Journal: Frontiers in genetics

Published: November 23, 2025

Cyclin D1 and the resistance landscape of HIF2 inhibition in clear-cell renal cell carcinoma: Insights from a mini-review.

Cyclin D1 and the resistance landscape of HIF2 inhibition in clear-cell renal cell carcinoma: Insights from a mini-review.

Journal: Biochemical and biophysical research communications

Published: November 18, 2025

Belzutifan as a new option in pheochromocytomas and paragangliomas.

Belzutifan as a new option in pheochromocytomas and paragangliomas.

Journal: Nature reviews. Clinical oncology

Published: October 28, 2025

Development of a Stability-Indicating HPLC Method for Quantification of Belzutifan and Its Related Impurities With LC-MS/MS Characterization of Degradation Products.

Development of a Stability-Indicating HPLC Method for Quantification of Belzutifan and Its Related Impurities With LC-MS/MS Characterization of Degradation Products.

Journal: Biomedical chromatography : BMC

Published: October 22, 2025

Belzutifan for Advanced Pheochromocytoma or Paraganglioma.

Belzutifan for Advanced Pheochromocytoma or Paraganglioma.

Journal: The New England journal of medicine

Published: October 22, 2025

Update on Systemic Therapies for Metastatic/Unresectable Pheochromocytomas and Paragangliomas and Future Directions.

Update on Systemic Therapies for Metastatic/Unresectable Pheochromocytomas and Paragangliomas and Future Directions.

Journal: Cancers

Published: October 15, 2025

Emerging Diagnostics and Therapies in Neuroendocrine Neoplasms: A Critical Review.

Emerging Diagnostics and Therapies in Neuroendocrine Neoplasms: A Critical Review.

Journal: Cancers

Published: October 15, 2025

Updated 2025 French Guidelines for Renal Cell Carcinoma.

Updated 2025 French Guidelines for Renal Cell Carcinoma.

Journal: The French journal of urology

Published: October 10, 2025

Updated 2025 French guidelines for renal cell carcinoma.

Updated 2025 French guidelines for renal cell carcinoma.

Journal: The French journal of urology

Published: October 10, 2025

HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors.

HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors.

Journal: bioRxiv : the preprint server for biology

Published: September 18, 2025

Showing 1-12 of 200

Last Updated: 02/24/2026